9-valent human papillomavirus vaccine

Phase 2

RRush University Medical Center

9-valent human papillomavirus vaccine is one of 2 therapeutic programs targeting Warts. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

WartsActive, not recruiting

WartsPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Warts

#DrugCompanyPhaseTrials

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 2

9-valent human papillomavirus vaccine

RRush University Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Warts

NCT07806617

Clinical

Trials by Indication[1]

Warts1 trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Intralesional Gardasil-9 Vaccine for the Treatment of Recalcitrant Verrucae

Active, not recruiting·RRush University Medical Center·Phase 2·NCT07806617·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 9-valent human papillomavirus vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 9-valent human papillomavirus vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Rush University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRush University Medical Center

9-valent human papillomavirus vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Warts1 trial

References

Drug Info

Quick Facts

Related News